Axogen, Inc.

NasdaqCM:AXGN Voorraadrapport

Marktkapitalisatie: US$611.4m

Axogen Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Axogen has been growing earnings at an average annual rate of 4.2%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 10.7% per year.

Belangrijke informatie

4.2%

Groei van de winst

6.4%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.9%
Inkomstengroei10.7%
Rendement op eigen vermogen-17.3%
Nettomarge-9.5%
Volgende winstupdate07 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16
Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Sep 10
We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Aug 09
Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Jan 13
AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Sep 10
Is AxoGen (NASDAQ:AXGN) A Risky Investment?

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Aug 02

Axogen estimates Q2 revenue above consensus, reaffirms guidance

Jul 18

Opbrengsten en kosten

Hoe Axogen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:AXGN Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24173-1712129
31 Mar 24164-2112129
31 Dec 23159-2212128
30 Sep 23152-2311827
30 Jun 23148-2311627
31 Mar 23144-2511627
31 Dec 22139-2911727
30 Sep 22134-2911327
30 Jun 22128-3211126
31 Mar 22127-3211025
31 Dec 21127-2710624
30 Sep 21128-2810823
30 Jun 21131-2210621
31 Mar 21119-229919
31 Dec 20112-249618
30 Sep 20108-259418
30 Jun 20103-299518
31 Mar 20108-2810018
31 Dec 19107-2910318
30 Sep 19102-279716
30 Jun 1996-269216
31 Mar 1990-268714
31 Dec 1884-228012
30 Sep 1877-207210
30 Jun 1871-18658
31 Mar 1865-12587
31 Dec 1760-10527
30 Sep 1755-14496
30 Jun 1750-14465
31 Mar 1745-14425
31 Dec 1641-14394
30 Sep 1638-12364
30 Jun 1634-13344
31 Mar 1630-13314
31 Dec 1527-13293
30 Sep 1524-16263
30 Jun 1521-16233
31 Mar 1519-17213
31 Dec 1417-18203
30 Sep 1415-15193
30 Jun 1413-16183
31 Mar 1412-15173
31 Dec 1311-15162

Kwaliteitswinsten: AXGN is currently unprofitable.

Groeiende winstmarge: AXGN is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: AXGN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.2% per year.

Versnelling van de groei: Unable to compare AXGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: AXGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).


Rendement op eigen vermogen

Hoge ROE: AXGN has a negative Return on Equity (-17.28%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden